Ship in Europe, Find out rates!
Oral mucosal spray based on Flurbiprofen .
Fluractive 0.25% Flurbiprofen Spray is used in the symptomatic treatment of irritative-inflammatory states also associated with oropharyngeal pain (eg gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.
Administer 2 sprays 3 times a day addressed directly to the affected area.
Symptoms of overdose may include nausea, vomiting and gastrointestinal irritation. Treatment should include gastric lavage and, if necessary, correction of the serum electrolyte picture. There is no specific antidote for flurbiprofen.
The following undesirable effects have been reported, particularly after administration of formulations for systemic use:
- Blood and lymphatic system disorders
- Disorders of the immune system
- Psychiatric disorders
- Nervous system disorders
- Acoustic and labyrinth disturbances
- Cardiovascular disorders
- Respiratory, thoracic and mediastinal disorders
- Gastrointestinal disorders
- Skin and subcutaneous tissue disorders
- Kidney and urinary tract disorders
Inhibition of prostaglandin synthesis can adversely affect pregnancy and / or embryo / fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was considered to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, flurbiprofen should not be administered except in strictly necessary cases. If flurbiprofen is used by a woman attempting to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible.
During the third trimester of pregnancy, all prostaglandin synthesis inhibitors can expose the fetus to:
the mother and the newborn, at the end of pregnancy, to:
Consequently flurbiprofen is contraindicated during the third trimester of pregnancy
Flurbiprofen is excreted in breast milk; however the amount excreted is only a small fraction of the maternal dose. Administration of flurbiprofen is not recommended in nursing mothers.
At the recommended doses, any swallowing of Fluractive 0.25% Mouthwash and Fluractive 0.25% Spray for oral mucosa does not cause any harm to the patient as these doses are well below those of the single systemic dosage of the product.
During the first and second trimester of pregnancy, flurbiprofen should not be administered except in strictly necessary cases. Administration of flurbiprofen is not recommended in nursing mothers.
The use of Fluractive 0.25% Mouthwash and Fluractive 0.25% Spray for oral mucosa, especially if prolonged, can give rise to sensitization or local irritation phenomena; in such cases it is necessary to interrupt the treatment and consult the doctor to establish, if necessary, a suitable therapy.
Do not use for prolonged treatments. After short periods of treatment without appreciable results, consult your doctor.
Mouthwash and oral mucosal spray contain para-hydroxybenzoates which can cause allergic reactions (including delayed ones). Patent V blue dye (E131) can cause allergic reactions. Polyoxyethylenated 40-hydrogenated castor oil can cause localized skin reactions. Both the mouthwash and the spray contain a small amount of ethyl alcohol, less than 100 mg per dose.
The expiry date indicated refers to the product in intact and correctly stored packaging. Shelf life after first opening the bottle is 21 weeks.
Warning : do not use Fluractive Spray after the expiry date stated on the package
100 ml of Fluractive Spray contain:
Flurbiprofen 0.25 g
Glycerol (98%), ethanol, non crystallizable liquid sorbitol, hydrogenated castor oil-40 polyoxyethylenate, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint flavor, patent blue V (E131), anhydrous citric acid, sodium hydroxide, purified water.
Destination | Cost | Detail |
---|---|---|
Italy | €5,90 | 24/72H |
Austria, Belgium, France, Germany, Netherlands, Poland, Czech Republic | € 12* | 3 days |
Denmark,Luxembourg,Portugal,Slovakia,Spain,Hungary | € 16* | 4 days |
Bulgary,Croatia,Estonia,Finland,Greece,Ireland,Lithuania,Romania,Slovenia,Sweden | € 27* | 5 days |
Canada, Switzerland, United Kingdom, USA | € 45 | 7 Days |